PHILADELPHIA, PA — Aro Biotherapeutics plans to begin clinical testing in 2027 of an experimental RNA-based treatment for inflammatory myositis after laboratory and preclinical studies identified a potential therapeutic target associated with muscle inflammation and disease activity.
The Philadelphia biotechnology company presented findings from its collaboration with Sweden’s Karolinska Institute at the American College of Rheumatology’s ACR Convergence 2026 meeting in Orlando, Florida, last week.
The research examined the CD40/CD40L signaling pathway, which regulates immune responses, and evaluated whether Aro’s investigational treatment, ABX1200, could suppress CD40 expression in muscle and inflammatory immune cells.
Analysis of muscle samples from patients with idiopathic inflammatory myopathies found elevated CD40 expression in those with inclusion body myositis, a form of inflammatory muscle disease.
Researchers also identified CD40L expression in certain circulating T cells and immune cells infiltrating affected muscle tissue. Additional testing found CD40 expression associated with macrophages present in inflamed muscle.
Higher CD40 expression correlated with elevated serum creatine kinase levels and disease activity scores, suggesting a relationship between the signaling pathway and the severity of muscle inflammation.
The findings provided a biological rationale for investigating CD40 suppression as a potential treatment strategy, although the observed associations do not establish that blocking the pathway will improve patient outcomes.
Aro’s ABX1200 uses small interfering RNA, or siRNA, designed to reduce production of CD40 by targeting its messenger RNA. The treatment combines that mechanism with the company’s Centyrin delivery technology, which is intended to direct the therapy toward skeletal muscle and inflammatory immune cells.
In laboratory experiments, ABX1200 reduced CD40 messenger RNA expression in macrophages and myotubes, which are developing muscle cells.
In a preclinical model of muscle inflammation, the treatment also reduced increases in CD40 expression and inflammatory signaling proteins associated with myositis.
“Because myositis is a muscle disease, patients stand to benefit from the development of muscle-targeted therapies like ABX1200, and this collaboration has taken steps to advance this approach,” said Dr. Ingrid Lundberg, professor of rheumatology at the Karolinska Institute.
The research remains at a preclinical stage. ABX1200 has not undergone clinical testing to establish its safety or effectiveness in patients, and no regulatory authority has evaluated it for those purposes.
“These data provide evidence that ABX1200 may represent a promising approach for inflammatory myositis patients,” said Purnanand Sarma, Aro Biotherapeutics’ chief executive officer.
The company intends to initiate clinical studies in 2027, advancing the program from laboratory and preclinical research into human testing.
Myositis encompasses several autoimmune disorders in which the immune system attacks skeletal muscle, causing chronic inflammation and progressive weakness.
Major forms include dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy and inclusion body myositis.
The diseases can affect muscles involved in movement, swallowing and breathing. Patients may also experience fatigue, joint pain, swelling and, in some forms, skin abnormalities.
There is no cure for myositis. Existing treatments generally focus on controlling inflammation and managing symptoms through corticosteroids, immunosuppressive medications, intravenous immunoglobulin and physical therapy.
Aro’s development program is examining whether targeted suppression of CD40 could provide another approach to treating the underlying inflammatory processes associated with these diseases.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.
